An Official Website of the United States Government
Search
Narrow Search Filters:
Year:2010
Company: Paramount Solutions Inc. Agency/Program/Year/Phase: DOD / SBIR / 2010 / 1
Abstract: This report describes the approach for an innovative Decision Aid Support System (DASS) that will provide evasive recommendations for the Commanding Officer (CO), Officer of the Deck (OOD), and tracking party during the critical time that occurs immediately following the detection of a possible… more
Company: ISOTHERAPEUTICS GROUP, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Bone-seeking radiopharmaceuticals are used extensively for bone pain palliation and have shown promise for treating bone metastases. They typically combine a radioactive metal such as samarium-153 with a chelator. The
chelator part of the molecule is taken up… more
Company: IOSEMANTICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Twenty-five years ago, a two-year old with liver failure had no medical or surgical options for survival. Now, with rapid advances in hepatology, surgical techniques, and pharmacology, the same two-year old can receive
a liver transplant and, with ongoing… more
Company: GENOMIC SYSTEMS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: Most patients who die from cancer succumb to advanced metastatic cancer. These patients, are mostoften treatment-refractory, and comprise the largest untapped market in cancer. We have developed a uniquely effective anti-PECAM-1 monoclonal antibody (mAb)-based therapy. To our knowledge, this mAb… more
Company: Agricultural Resch Init Agency/Program/Year/Phase: NSF / STTR / 2010 / 1
Abstract: This Small Business Technology Transfer (STTR) Phase I project proposes to develop a novel bionematicide to control soybean cyst nematode (SCN) in soybeans. In wide-ranging preliminary research, this bionematicide controlled several nematode stages, including up to 90% of cysts (the primary… more
Company: STANDARD IMAGING, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Standard Imaging, Inc. is developing a new generation of radiation dosimeters for small field dosimetry, which are needed in clinical applications such as stereotactic radiosurgery/ stereotactic radiotherapy (SRS/SRT),
intensity modulated radiation therapy… more
Company: HELICOS BIOSCIENCE CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Tremendous advances in genomics during the past two decades hold great potential for the development of new health innovations. For this potential to be realized in the form of advances in biomedical research and novel
prevention, diagnosis, treatment and… more
Company: MCP Agency/Program/Year/Phase: NSF / SBIR / 2010 / 1
Abstract: This Small Business Innovation Research (SBIR) Phase I project will develop a process for modifying macrolide natural products in general and Rapamycin in particular using a relatively new chemical transformation called the ring contraction metathesis reaction. The modified compounds will contain a… more
Company: KDT, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: Toxic compounds are a major health hazard in our environment, in our food, and in our pharmaceuticals. Identifying toxic compounds is currently time-consuming, expensive and complicated by animal rights issues. We propose to generate a set of 96 transgenic nematodes that will contain… more
Company: HEMOSHEAR, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Atherosclerosis is a vascular inflammatory disease characterized by dramatic changes in endothelial cell (EC) and smooth muscle cell (SMC) phenotypes. The progression of atherosclerosis is dependent on interactions bet
ween vascular cells (EC/SMC), regional… more
Company: ASPEN MEDISYS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: Certain magnetic nanoparticles produce substantial heat under high strength alternating magnetic fields. These particles will be introduced into the body such that they accumulate in cancerous tissues. Ovarian cancer is characterized by an abundance of immunosuppressive phagocytes. Nanoparticles… more
Company: CARMOT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Protein-protein interactions represent the largest untapped opportunity for therapeutic development. The number of protein-protein interactions in human cells has been estimated to exceed 100,000, well above the ~30,000
human genes. This multitude of… more
Company: CELSION CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The overall objective of this SBIR Phase 1 grant is to finalize the formulation design for a carboplatin-loaded Low Temperature Sensitive Liposome (LTSL-carboplatin) and demonstrate the effectiveness of the optimized pr
oduct combined with HyperThermia (HT), to… more
Company: SILAGENE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The goal of Phase I of this SBIR application is to establish the feasibility of using a newly invented gene silencing technology called U1 Adaptors that uses Adaptor oligonucleotides to silence the human BCL2 gene, a ke
y player in tumor progression. The long… more
Company: VET THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Since drug candidates that often effectively shrink tumor bulk in murine xenograft models are unable to eliminate the disease in the humans, it has become absolutely critical to develop novel and more predictive pre-c
linical models. The goal of this proposal… more
Company: KRYPTOS MEDICAL CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Breast cancer-related death results from complications due to metastatic growth. Therapies for metastatic patients focus on extending survival and controlling symptoms, and the choice of therapies is frequently based on
particular target-proteins found in the… more
Company: ADURO BIOTECH Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Melanoma is one of the most rapidly growing cancers worldwide with an estimated 8,420 deaths and 62,480 new cases in the United States in 2008 alone. While melanoma can be surgically removed when detected early, there i
s no cure for advanced or metastatic… more
Company: BAIR TRACKS AND COMPANY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Sexual violence perpetrated against women is a serious public health problem. Among female adolescents rates as high as 53% for some types of sexual violence have been reported. Moreover, young women are assaulted or raped most often by someone they know and… more
Company: Aqua Resources Corporation Agency/Program/Year/Phase: DOD / SBIR / 2010 / 1
Abstract: The dynamics of nano-size interactions of metal hydroxide nanoplatelets is a new field of material science. Initial research conducted by Aqua Resources and the Department of Defense, offers the promise of an innovative means of effectively defending against Chemical/Biological (CB) warfare agents… more
Company: J AND J SOLUTIONS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Drugs used for cancer chemotherapy tend to be highly cytotoxic and genotoxic, with well-documented carcinogenic, mutagenic, and teratogenic effects. Long-term, occupational exposure to these highly toxic drugs presents
serious health risks to the healthcare… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic
paradigm, the ability to apply this… more
Company: JADEN BIOSCIENCE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): The ROR1 cell surface biomarker is expressed on B-cell Chronic Lymphocytic Leukemia (B-CLL) cells but not on healthy B-cells or other white blood cells (WBCs) in B-CLL patients. We propose to develop an inexpensive, eas
y-to-use, rapid, ultrasensitive assay… more
Company: TOPH BIOLOGICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide and the incidence in the United States is increasing. It has been estimated that the number of cases of HCC will continue to increase
by 81% (from a baseline of about 13,000 a… more
Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: Kinase inhibitors such as Gleevec and Tarceva have markedly improved cancer therapy. Essential to the use of such inhibitors are companion diagnostics enabling determination of the mutational status of th eir kinase targets in tumors. Anaplastic lymphoma kinase (ALK) fusion oncogenes have emerged… more
Company: TITAN PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with a loss of dopaminergic nigrostriatal neurons. There are over 1.5 million PD patients in the US, with about 50,000 new patients each ye
ar. The cornerstone of symptomatic… more
HELP FOR NARROW YOUR SEARCH
Search Options
Search for Either Criteria
Narrowing the Search Results
Search Options
There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.
Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.
Search for Either Criteria
When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.
Narrowing the Search Results
You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.